The outstanding research of He and co-workers1 provided the first evidence that mutated TET2 and its downstream protein MBD6 regulate the chromatin structure in leukaemias which will pave the way for the development of highly specific novel therapeutic approaches for TET2-mutated haematological cancers in the near future. This evidence concerns the gene MBD6 and leukemia.